Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease.
A yeast artificial chromosome (YAC) mouse model of Huntington's disease (YAC128) develops motor abnormalities, age-dependent striatal atrophy and neuronal loss. Alteration of neurotransmitter receptors, particularly glutamate and dopamine receptors, is a pathological hallmark of Huntington's disease. We therefore analyzed neurotransmitter receptors in symptomatic YAC128 Huntington's disease mice. We found significant increases in N-methyl-d-aspartate, AMPA and metabotropic glutamate receptor binding, which were not due to increases in receptor subunit mRNA expression levels. Subcellular fractionation analysis revealed increased levels of glutamate receptor subunits in synaptic membrane fractions from YAC128 mice. We found no changes in dopamine, GABA or adenosine receptor binding, nor did we see alterations in dopamine D1, D2 or adenosine A2a receptor mRNA levels. The receptor abnormalities in YAC128 transgenic mice thus appear limited to glutamate receptors. We also found a significant decrease in preproenkephalin mRNA in the striatum of YAC128 mice, which contrasts with the lack of change in levels of mRNA encoding neurotransmitter receptors. Taken together, the abnormal and selective increases in glutamate receptor subunit expression and binding are not due to increases in receptor subunit expression and may exert detrimental effects. The decrease in preproenkephalin mRNA suggests a selective transcriptional deficit, as opposed to neuronal loss, and could additionally contribute to the abnormal motor symptoms in YAC128 mice.
Benn
C L
CL
MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129-4404, USA.
Slow
E J
EJ
Farrell
L A
LA
Graham
R
R
Deng
Y
Y
Hayden
M R
MR
Cha
J-H J
JH
D000818:Animals; D001345:Autoradiography; D015153:Blotting, Western; D018244:Chromosomes, Artificial, Yeast / Q000235:genetics*; D004745:Enkephalins / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000235:genetics* / Q000503:physiopathology*; D017403:In Situ Hybridization; D051379:Mice; D008822:Mice, Transgenic; D011498:Protein Precursors / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D018091:Receptors, AMPA / Q000378:metabolism; D011954:Receptors, Dopamine / Q000378:metabolism; D018079:Receptors, GABA / Q000378:metabolism; D017470:Receptors, Glutamate / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D013347:Subcellular Fractions / Q000378:metabolism
D004745:Enkephalins; D011498:Protein Precursors; D012333:RNA, Messenger; D018091:Receptors, AMPA; D011954:Receptors, Dopamine; D018079:Receptors, GABA; D017470:Receptors, Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D018047:Receptors, Purinergic P1; C033660:preproenkephalin